Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maurice Nahabedian

Plastic and Reconstructive Surgery Mc Lean, VA Medical Doctor

NPI 1265418990 CMS profile 56707

7601 Lewinsville Rd Ste 400, Mc Lean, VA 22102

Open in the dashboard

General payments

$827,515

672 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maurice Nahabedian of Mc Lean, VA is reported in the CMS Open Payments database as having received $827,515 across 672 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $145,362 99
2024 General $88,050 69
2023 General $89,903 59
2022 General $68,234 62
2021 General $92,932 83
2020 General $78,339 74
2019 General $264,696 226

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maurice Nahabedian
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Maurice Nahabedian were reported at $145,362. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Maurice Nahabedian Plastic and Reconstructive Surgery median Middle half National median
2019 $264,696 $335 $121–$1,264 $163
2020 $78,339 $162 $57–$417 $114
2021 $92,932 $245 $89–$735 $132
2022 $68,234 $325 $120–$932 $149
2023 $89,903 $343 $129–$999 $160
2024 $88,050 $390 $141–$1,085 $164
2025 $145,362 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $425,914 380 payments
  2. AbbVie, Inc. $257,107 155 payments
  3. Stryker Corporation $59,565 29 payments
  4. Davol Inc. $45,317 32 payments
  5. PolarityTE, Inc. $32,850 1 payment
  6. Merz North America, Inc. $1,269 10 payments
  7. Integra LifeSciences Corporation $626 7 payments
  8. Motiva USA, LLC $579 8 payments
  9. Smith+Nephew, Inc. $557 4 payments
  10. Mentor Worldwide LLC $424 9 payments
  11. Other $3,308 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $499,008 133 payments
  2. Consulting Fee $221,425 106 payments
  3. Travel and Lodging $44,152 142 payments
  4. Honoraria $42,900 9 payments
  5. Food and Beverage $20,030 282 payments
Products named General payments · program years 2019–2025
  1. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $262,381 154 payments
  2. NATRELLE $148,226 176 payments
  3. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $139,934 124 payments
  4. ALLODERM $115,873 96 payments
  5. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $110,058 64 payments
  6. REVOLVE $103,680 83 payments
  7. STRATTICE $92,340 73 payments
  8. SPY-PHI SYSTEM $36,800 7 payments
  9. SkinTE $32,850 1 payment
  10. SPY TECHNOLOGY $20,612 15 payments
  11. Other $47,185 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$51,626

Medicare's payments for the services billed

Medicare patients

48

Average age 71

Services billed

184

48 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 56%
Arthritis 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
$141 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

672 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record